Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
Clinical Pharmacology: Advances and Applications · 2016-02 · 9
DOI: 10.2147/cpaa.s98221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2016-02. Verfasst von Jonathan Q Tran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Biogen, Cambridge, MA, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology, Biogen, Cambridge, MA, USA.
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA; Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Global Biomarker Discovery and Development, Cambridge, MA, USA.
- Global Clinical Operation, Biogen, Maidenhead, Berkshire, UK.
- Global Clinical Development, Biogen, Cambridge, MA, USA.
Zitieren
APA
Tran, J. Q., Othman, A. A., Mikulskis, A., Wolstencroft, P., & Elkins, J. (2016). Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clinical Pharmacology: Advances and Applications, 9. https://doi.org/10.2147/cpaa.s98221
Vancouver
Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clinical Pharmacology: Advances and Applications. 2016:9. doi:10.2147/cpaa.s98221
BibTeX
@article{Tran2016,
author = {Tran, Jonathan Q and Othman, Ahmed A and Mikulskis, Alvydas and Wolstencroft, Paul and Elkins, Jacob},
title = {Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis},
journal = {Clinical Pharmacology: Advances and Applications},
year = {2016},
pages = {9},
doi = {10.2147/cpaa.s98221}
}
EUVIMED